AstraZeneca PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZN research report →
Range $206 – $216
Price Chart
About the company
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex.
- CEO
- Pascal Claude Roland Soriot
- IPO
- 1993
- Employees
- 96,100
- HQ
- Cambridge, CA, GB
AI snapshot
Six angles, distilled from the data.
AZN is in a constructive multi-month uptrend, trading above its 200-day average of 180.18 and 50-day average of 168.81. The shares sit near the upper end of the 52-week range, well above the 153.41 low and not far from the 209.11 high, which keeps the longer-term trend intact.
Street sentiment stays favorable: consensus is Buy with a 208.08 average target, implying modest upside from current levels. Recent changes have been mixed but constructive, including Nordea’s upgrade from Sell to Buy and new Outperform starts from RBC Capital and CICC, even as a few firms trimmed ratings.
The earnings pattern is solid, with 6 of the last 7 quarters beating EPS estimates and the last three reported quarters all topping consensus. Next-year EPS is modeled at 11.32 versus 7.07 TTM, so shareholders should watch whether management can keep translating revenue growth into another clean beat.
The signal is neutral. Most filings are automatic award grants, while the only clear discretionary trade was a 20.233-share purchase in August 2026 and a much larger 11,893-share sale in May 2026 by the same officer, leaving no strong directional insider conviction.
Profitability is strong, with gross margin at 81.8%, operating margin at 25.8%, and net margin at 17.68%. Growth is still healthy too, with revenue up 6.7% year over year and earnings up 23.5%, while free cash flow reached $20.48 billion in fiscal 2025.
AZN screens as a high-quality large-cap pharma name with a 22.57% ROE and 7.16% free-cash-flow yield, supported by strong margins. Versus the sector, the setup favors premium valuation rather than deep value, with the stock trading at 19.87 times earnings.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $270.39B
- P/E
- 24.48
- Fwd P/E
- 17.00
- PEG
- 1.48
- P/S
- 4.33
- P/B
- 5.26
- EV/EBITDA
- 13.88
- Div Yield
- 1.80%
- Gross Margin
- 77.59%
- Op Margin
- 23.60%
- Net Margin
- 17.69%
- ROE
- 22.31%
- ROIC
- 13.07%
Latest fiscal year · YoY change
- Revenue
- $58.74B+8.6%
- Gross Profit
- $48.11B+9.7%
- Op Income
- $13.74B
- Net Income
- $10.26B+45.8%
- EPS
- $6.60+45.4%
- OCF Growth
- +22.9%
- FCF Growth
- +19.2%
- 52W High
- $212.71
- 52W Low
- $153.41
- 50D MA
- $170.43
- 200D MA
- $180.06
- Beta
- 0.21
- RSI (14)
- 44
- Avg Volume
- 2.95M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AstraZeneca reported continued broad-based growth in the first nine months of 2026, with revenue up 7%, core EPS up 14%, and management increasingly confident in its 2030 growth plan thanks to multiple Phase III successes and new launches.· October 30, 2026
- Total revenue rose 7% in the first 9 months and core EPS increased 14%; excluding Farxiga and Brilinta, revenue grew 12%.
- Oncology, rare disease and R&I all delivered double-digit growth, helping offset LOE and China/VBP headwinds in CVRM.
- Management cited 12 positive Phase III readouts since February and 4 first approvals for new medicines, taking approved new molecular entities to 14.
- AstraZeneca reiterated full-year guidance for mid- to high-single-digit revenue growth and low-double-digit core EPS growth.
- The company announced a 3-year Reshaping for Sustainable Growth program with up to $2 billion of restructuring costs and $1.5 billion of annualized pretax run-rate benefits.
In the first 9 months of 2026, total revenue increased 7% and core EPS rose 14%; product revenue was up 6% and alliance revenue increased 32%. Core gross margin was 83% in the first 9 months, and management said it expects full-year core gross margin to be stable to slightly higher than in 2025. Cash flow from operating activities was $10.9 billion, CapEx was $2.3 billion, deal-related payments totaled $4.3 billion, and net debt-to-EBITDA was 1.2x. For the third quarter, oncology total revenue grew 16% to $21.9 billion in the first 9 months, while biopharmaceuticals revenue declined 6% in the quarter to $5.6 billion and rare disease grew 11% in the first 9 months to $7.5 billion. Full-year guidance was reiterated for total revenue growth of mid- to high-single digits and core EPS growth of low double digits; management also said core R&D should remain at the upper end of the low-20s percent of revenue, and CapEx is now expected to rise by low teens versus 2025.
Pascal Soriot framed the quarter as evidence that AstraZeneca’s commercial momentum and pipeline delivery are both strengthening, saying the company is increasingly confident in achieving its 2030 ambition and sustainable growth beyond that. He emphasized that the 12 positive Phase III programs and 4 new approvals are reducing risk around future growth and that 2027 should be a very rich year with more than 20 high-value readouts. He also highlighted that the company is investing in new technologies, partnerships, and platform capabilities such as ADCs, bispecifics, cell therapies, and cancer vaccines to support growth beyond 2030.
Aradhana Sarin focused on the strength of the P&L and balance sheet, citing 83% core gross margin in the first 9 months and saying full-year margins should be stable to slightly higher than 2025 despite second-half seasonality and China budget effects. She said core R&D expense rose 5% year-to-date, SG&A rose 4%, and overall core operating expenses increased 5%, while cash flow from operations was lower mainly because of the prior-year Lynparza milestone and working capital effects from Farxiga LOE. She also said CapEx is now expected to increase by low teens versus 2025, deal-related payments were $4.3 billion, milestone payments should be about $2.5 billion for the full year, and the company remains comfortable with gross debt and a 1.2x net debt-to-EBITDA ratio.
Analysts pressed on the size and concentration of the more than $20 billion non-risk-adjusted peak revenue opportunity, and Pascal said Datroway is important but not the main driver; he stressed the pipeline is diversified across multiple products and indications. Questions also focused on the $2 billion restructuring program, with management saying it is a broad resource realignment across units, has a cash-cost profile, and is meant to create room for future investment. Other notable exchanges covered Imfinzi subcutaneous timing, where management said it should launch before IV LOE, China competitive dynamics, where AstraZeneca sees both headwinds and tailwinds but expects its own China outlook to remain positive, and Tagrisso’s future, where management sees SAFFRON, SANOVO and Datroway combinations extending the franchise.
The bullish case from this call is that AstraZeneca is still growing across multiple major franchises while its late-stage pipeline is producing enough readouts to keep the next several years full of catalysts. Management pointed to more than $10 billion of non-risk-adjusted peak year sales potential already de-risked by positive data, plus a 2027 pipeline with more than $20 billion of potential peak revenue across the portfolio. The call also reinforced confidence in long-term growth through 2030 and beyond, supported by broad geographic momentum, new launches, and a strong balance sheet.
The main risks discussed were the expected headwinds from Farxiga and Brilinta LOE, continuing China VBP pressure, and some product-specific competitive issues such as generic Symbicort and the IRA impact on Calquence in 2027. Management also noted higher operating expenses in the fourth quarter, persistent working-capital effects from Farxiga, and a sequential step-up in finance expenses. On the pipeline side, Pascal repeatedly reminded investors that not everything will work, and the company is still waiting for key 2027 readouts to further validate its post-2030 growth case.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 1.55B
- Float Shares
- 1.54B
of shares held by institutions
1,529 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AZN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 31, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Dec 8, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 18, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 19, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Oct 21, 25 | Filing → |
| Val HoyleHouse · OR04 | Sell | Sep 23, 25 | Filing → |
| Val HoyleHouse · OR04 | Buy | Oct 29, 24 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 9, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jul 22, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 17, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Investor Ab | 51.59M | 0 |
| Vanguard Capital Management LLC | 45.66M | ▲ 270.65K |
| Norges Bank | 33.86M | ▲ 33.86M |
| Capital World Investors | 31.09M | ▲ 1.01M |
| Wellington Management Group Llp | 30.84M | ▲ 2.30M |
| Fmr LLC | 29.38M | ▲ 487.83K |
| Legal & General Group PLC | 26.18M | ▲ 433.97K |
| Price T Rowe Associates Inc | 19.29M | ▲ 2.67M |
| Vanguard Asset Management, Ltd | 19.12M | ▲ 404.13K |
| Franklin Templeton Inc | 19.05M | ▲ 2.54M |
| Jpmorgan Chase & Co | 18.43M | ▼ 776.61K |
| Primecap Management Co | 18.11M | ▲ 13.37K |
Held by 250 ETFs
Biggest fund positions in AZN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Sharma Mani | other | 1 |
| Oct 6, 26 | Sharma Mani | other | 2 |
| Sep 8, 26 | Sharma Mani | other | 1 |
| Aug 8, 26 | Sharma Mani | buy | 20.233 |
| Aug 6, 26 | Sharma Mani | other | 2 |
| Jul 6, 26 | Sharma Mani | other | 2 |
| Jun 8, 26 | Sharma Mani | other | 1 |
| May 20, 26 | Sharma Mani | sell | 11,893 |
| May 6, 26 | Sharma Mani | other | 1 |
| Apr 7, 26 | Sharma Mani | other | 1 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AZN coverage
Recent articles, reports, and earnings notes.

AstraZeneca (AZN): Oncology Growth Supports a Buy
AstraZeneca earns a Buy as oncology and rare disease offset BioPharmaceuticals pressure. The stock looks reasonably valued with strong cash flow and a clear growth mix shift.

Windward Bio Group AG IPO: The Bull and Bear Case
Windward Bio Group AG (NASDAQ: WWB) is expected to list on November 13, 2026, on the Nasdaq exchange, with the price range not disclosed. The setup is straightforward: a clinical-stage biotech with a differentiated dosing story, but no revenue and heavy trial risk.

AstraZeneca PLC (AZN) rises 7% after strong earnings
AstraZeneca PLC (AZN) rises after reporting stronger-than-expected quarterly earnings and reaffirming full-year guidance. The stock’s move reflects investor confidence in 7% nine-month revenue growth, double-digit core EPS gains, and continued pipeline momentum, especially in oncology. Trading volume also points to meaningful follow-through.
Want a deeper read on AZN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
zacks.com · Nov 20
Allspring Large Cap Growth Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 18
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
zacks.com · Nov 17
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
zacks.com · Nov 16
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
barrons.com · Nov 16
Breakfast News: Summit’s FDA Setback Isn’t the End
fool.com · Nov 16
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
businesswire.com · Nov 13
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
reuters.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice